Novel Treatment Advances in Differentiated Thyroid Cancer
An overview of therapies in the pipeline for differentiated thyroid cancer and their potential effect on clinical decision-making.
Read More
Dr. Brose on Lenvatinib in Differentiated Thyroid Cancer
October 22nd 2015Marcia Brose, MD, PhD, associate professor of Otorhinolaryngology, Head and Neck Surgery, at the Hospital of the University of Pennsylvania, discusses survival benefit and possible combination strategies with the lenvatinib in patients with radioactive iodine refractory differentiated thyroid cancer.
Read More